Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

GYM329

Phase 1Small molecule

GYM329 is one of 34 small molecule programs targeting Atrophy. It is currently in Phase 1.

1

Indications

1

Total Trials

0

Active Trials

33

Competitors

Pipeline

Status by Indication[3][1]

Indication

AtrophyActive, not recruiting

AtrophyPhase 1

Active, not recruiting

Competition

Competitive Landscape

72 competitors in Atrophy

#DrugCompanyPhaseTrials

Namenda

Zoladex

TTerSera Therapeutics LLC

Botox

Intrarosa

Alnylam Pharmaceuticals

Actos

Activella

Pitocin

Avandia

Alnylam Pharmaceuticals

Prometrium

Avodart

Akero Therapeutics

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atrophy1 trial

A Clinical Pharmacology Study to Evaluate the Effect of GYM329 on Disuse Muscle Atrophy in Healthy Volunteer

Completed· Roche logo

Roche·Phase 1·NCT04708847·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GYM329. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GYM329 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GYM329. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Roche

Related News